Gambia vs Timor-Leste: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Gambia
82.0%
in 2025
Timor-Leste
82.0%
in 2025
Gambia rank
106th
Timor-Leste rank
106th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Gambia
- Timor-Leste
How they compare
Gambia currently reports 82.0% against 82.0% in Timor-Leste, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Timor-Leste ahead.
Gambia ranks 106th and Timor-Leste ranks 106th of 194 countries.
Gambia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Gambia | Timor-Leste | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 94.6% | 0.0% | 94.6% | Gambia |
| 2020s | 79.7% | 36.5% | 43.2% | Gambia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Gambia or Timor-Leste?
- Gambia, at 82.0% against 82.0% in Timor-Leste as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Gambia and Timor-Leste?
- 0.0%, with Gambia ahead.
- How many years of comparable data are there for Gambia and Timor-Leste?
- 18 years are reported by both, from 2008 to 2025.
- How do Gambia and Timor-Leste rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Gambia ranks 106th and Timor-Leste ranks 106th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.